{"entity":{"id":"nct00678119","kind":"trial","name":"Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment","aka":[],"tldr":"A phase 2 trial of Rocapuldencel-T run by Argos Therapeutics, completed.","summary":"Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment is a phase 2 interventional study registered as NCT00678119 by Argos Therapeutics, with 25 participants enrolled, started 2008-01. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003 and Sunitinib.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT00678119","url":"https://clinicaltrials.gov/study/NCT00678119"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00678119","phase":"2","setting":"A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib","sponsor":"Argos Therapeutics","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00678119/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}